Skip to main content
OpenTrials
Completed

NCT Number: NCT01823822

Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa

This multicentre, randomised, double-blind, 2-parallel group, controlled trial aims to investigate whether oral milk protein supplements led to increase in serum Insulin-like Growth Factor-I levels (IGF-I) as compared with a control group fed with an iso-caloric supplement, in women with anorexia nervosa. Subjects receive either 150g/day of tested product or control product for 4-week, followed by a 4-week follow-up.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Bone Diseases Service, Geneva University Hospitals

Geneva, Switzerland

About this study

Study centres: 4 active centres in France and 2 active centres in Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged between 18 to 40 years (bounds included).
  • Women with a serum IGF-I level below the 25th percentile of the reference value according to the age (bounds included).
  • Women who had given written inform consent.
  • Women with DSM-IV-confirmed anorexia nervosa lasting for at least 6 months. Women with concomitant binge eating and purging type are also included.
  • Women admitted in-hospital for weight and nutritional rehabilitation. It is anticipated that the patient will stay in-hospital during the full duration of the 4-week supplementation phase, and at least 5 weeks within the study.
  • Women being already regular consumers of dairy products.
  • For women with childbearing potential, use of a contraceptive method.
  • Discontinuation of any mineral and vitamin supplements containing calcium and vitamin D, 1 week before starting the product consumption and during the study.

Exclusion criteria

  • Women with primary amenorrhea;
  • Women with lactose intolerance;
  • Women with any other metabolic disease that could affect bone metabolism: osteogenesis imperfecta, Paget's disease of bone, hyperthyroidism, primary hyperparathyroidism;
  • Women with current or past neoplasm;
  • Women with any other severe comorbidity;
  • Pregnant or breast feeding women;
  • Women with epilepsy;
  • Women with any current or past use of the following treatments: bisphosphonates, calcitonin, steroids;
  • Patients enrolled in another clinical study within the last 4 weeks;
  • Patients having already received oral nutritional supplements or who need to receive other oral or intravenous (IV) supplements during the follow-up;
  • Patients having received oral or IV nutritional supplements within two weeks before the inclusion;
  • Patients having willed to participate in another clinical study during the present study phase and 4 weeks after the end of their participation in the present study.

Treatment and study plan

Oral protein supplement (Tested product)

Dietary Supplement

Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.

Iso-caloric supplement (Control product)

Dietary Supplement

Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.

Primary outcomes

  1. Serum insulin like growth factor-1 (IGF-I) level

    Time frame: 4-week

    The main study product effect criterion is the IGF-I level over the 4-week consumption period.

Sponsors and collaborators

Lead sponsor

University Hospital, Geneva

Other

Collaborators

  • Danone Global Research & Innovation Center

Registry information

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Apr 4, 2013
Registry last updated
Apr 4, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.